{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:21:53Z","timestamp":1760235713182,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K18048"],"award-info":[{"award-number":["JP20K18048"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Retroperitoneal sarcomas are rare neoplasms that occur in the retroperitoneum. Complete surgical resection is the only effective treatment option. The prediction of prognosis by histological diagnosis has not yet been established. The purpose of this study was to identify the usefulness of [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging for validating the prognosis of retroperitoneal sarcoma (RPS) established by histological diagnosis. Methods: We retrospectively reviewed 201 patients with RPS treated at the Osaka International Cancer Institute between 2010 and 2021. We extracted the clinical data, including standardized uptake values (SUVs), evaluated with FDG-PET, and statistically analyzed the data. Results: The median age of patients was 64 years (range, 31\u201385 years). A total of 101 (50.2%) patients were men, and 100 (49.8%) were women. Surgical resection was performed in 155 (77.1%) patients. On histological analysis, 75 (37.3%), 52 (25.9%), and 29 (14.4%) patients were diagnosed with dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma, respectively. The median survival time for patients with high maximum SUV (SUVmax) (\u22654) or low SUVmax (&lt;4) was 275.8 months and 79.5 months, respectively. Furthermore, among the patients with dedifferentiated liposarcoma, the overall survival rate for patients with high SUVmax (\u22654) was significantly lower than that of those with low SUVmax (&lt;4). Conclusions: The present study demonstrated that SUVmax calculated with FDG-PET was useful as a prognostic factor in RPS, especially in dedifferentiated liposarcoma and Grade2 RPS. To devise a treatment strategy for RPS, SUVmax during FDG-PET scan may be considered for clinical assessment.<\/jats:p>","DOI":"10.3390\/cancers13184611","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T21:47:21Z","timestamp":1631656041000},"page":"4611","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Toru","family":"Wakamatsu","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"},{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Imura","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"},{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironari","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"},{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"},{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Osaka 540-0006, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-5855","authenticated-orcid":false,"given":"Hidetatsu","family":"Outani","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Kakunaga","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Osaka 540-0006, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Osaka 540-0006, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, Japan"},{"name":"Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/107327481101800305","article-title":"Current diagnosis and management of retroperitoneal sarcoma","volume":"18","author":"Mullinax","year":"2011","journal-title":"Cancer Control"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000658-199809000-00008","article-title":"Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution","volume":"228","author":"Lewis","year":"1998","journal-title":"Ann. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3322\/canjclin.56.5.282","article-title":"Staging Soft Tissue Sarcoma: Evolution and Change. CA","volume":"56","author":"Kotilingam","year":"2006","journal-title":"Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1078-0432.CCR-18-2700","article-title":"Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: A study and novel nomogram from TARPSWG","volume":"25","author":"Raut","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2012.44.3747","article-title":"Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: Histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets","volume":"31","author":"Gronchi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.30572","article-title":"Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group","volume":"123","author":"MacNeill","year":"2017","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdr323","article-title":"Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ejso.2015.07.014","article-title":"Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma","volume":"41","author":"Miura","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","first-page":"717","article-title":"18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: A meta-analysis","volume":"44","author":"Ioannidis","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00259-010-1713-9","article-title":"A new dimension of FDG-PET interpretation: Assessment of tumor biology","volume":"38","author":"Kwee","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.sla.0000152663.61348.6f","article-title":"Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas","volume":"241","author":"Schwarzbach","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e5913","DOI":"10.1097\/MD.0000000000005913","article-title":"Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma a meta-analysis","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7191363","DOI":"10.1155\/2021\/7191363","article-title":"Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on 18F-FDG PET\/CT in Patients with Retroperitoneal Liposarcoma","volume":"2021","author":"Li","year":"2021","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/s41598-019-43215-5","article-title":"Maximum standardized uptake value on 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography improves outcome prediction in retroperitoneal liposarcoma","volume":"9","author":"Rhu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MNM.0000000000001002","article-title":"The role of 18F-FDG PET\/CT in soft tissue sarcoma","volume":"40","author":"Sambri","year":"2019","journal-title":"Nucl. Med. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jso.26379","article-title":"The role of 18F-FDG PET\/CT in retroperitoneal sarcomas-A multicenter retrospective study","volume":"123","author":"Subramaniam","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdp298","article-title":"Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent","volume":"21","author":"Anaya","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/cncr.25057","article-title":"Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma","volume":"116","author":"Ardoino","year":"2010","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s00259-006-0170-y","article-title":"Risk assessment in liposarcoma patients based on FDG PET imaging","volume":"33","author":"Brenner","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1245\/s10434-017-6136-4","article-title":"Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection","volume":"25","author":"Fairweather","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/SLA.0000000000002250","article-title":"Postoperative Morbidity after Radical Resection of Primary Retroperitoneal Sarcoma","volume":"267","author":"Macneill","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1541-7786.MCR-17-0182","article-title":"EWS\/FLI is a master regulator of metabolic reprogramming in Ewing sarcoma","volume":"15","author":"Tanner","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41389-019-0129-z","article-title":"Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth","volume":"8","author":"Issaq","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbrc.2018.10.119","article-title":"Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma","volume":"506","author":"Igarashi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-018-0583-2","article-title":"miR-133a function in the pathogenesis of dedifferentiated liposarcoma","volume":"18","author":"Yu","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study","volume":"13","author":"Blay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"a002386","DOI":"10.1101\/mcs.a002386","article-title":"Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin","volume":"4","author":"Beird","year":"2018","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1038\/s41467-019-13286-z","article-title":"Integrated exome and RNA sequencing of dedifferentiated liposarcoma","volume":"10","author":"Hirata","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4611\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:42Z","timestamp":1760166162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":30,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184611"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184611","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}